Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03612271 · ClinicalTrials.gov registry record · NA

mGlide RCT: A Clinical Glide Path To Close the Guideline-to-Practice Gap In HTN Management

A NA study of Hypertension, sponsored by University of Minnesota.

Active
Registry status
NA
Development phase
395
Enrollment target
1
Study location

NCT03612271 is a NA study of Hypertension that is active but no longer recruiting, run by University of Minnesota. The registered enrollment target is 395 participants, below the 3,507-participant average among 470 other Hypertension trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03612271, a NA study of Hypertension, is active but no longer recruiting, sponsored by University of Minnesota.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
395 participants
Enrollment target
1
Study location

Study Summary

Hypertension (HTN) is the most important stroke and cardiovascular disease (CVD) risk factor. Unfortunately, there is substantial under-treatment of HTN. Of the 86 million adults with prevalent HTN in the U.S., 40 million (46%) have inadequately controlled blood pressure (BP). This problem is worse among minority groups. In this study, the investigators demonstrate how mHealth (mobile health technology) can improve HTN control rates in stroke survivors and primary care patients without stroke, but who are at a high risk of stroke and CVD. Our intervention is called mGlide. Intervention participants will self- monitor their BP daily using a wireless BP monitor and a smart phone. The phone will transmit this BP to a database automatically. The investigators will use the framework of glide paths to manage the transmitted BP data. The glide path, based on the concept of landing an airplane, establishes an expected trajectory of BP readings for each patient with bounds set by guidelines and provider input. BP is monitored at home; the health care team is alerted when patient BP deviates from expected bounds. Alerts are generated once a week for the health care team with a list of patients with uncontrolled HTN. This facilitates early intervention while avoiding information overload. Partnering clinical centers include Federally Qualified Health Centers that serve low income and minority (Latino, African American, Hmong) communities. In this RCT study, the investigators will randomize 450 participants with uncontrolled HTN to the mGlide intervention (n=225) vs. state-of-clinical-care comparison (n=225).

Conditions Studied

Interventions

  • BEHAVIORAL mGlide

Study Locations (1)

Minnesota

  • Epidemiology Clinical Research Center - Minneapolis

Trial Details

FieldValue
Enrollment Target 395 participants
Start Date 2019-03-01
Est. Completion 2026-04-30
Phase NA

Sponsor

University of Minnesota

966 total trials

What the Registry Record Tells You About NCT03612271

The ClinicalTrials.gov registry entry for NCT03612271 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 395 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,507-participant average among 470 other Hypertension trials with a reported enrollment target (89% lower). The listed sponsor is University of Minnesota, which has 966 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Hypertension appearing as the primary indexed condition, and to 1 intervention - of which mGlide is the first listed.

NCT03612271 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.

Frequently Asked Questions

What is clinical trial NCT03612271 about?

NCT03612271 is a clinical study titled "mGlide RCT: A Clinical Glide Path To Close the Guideline-to-Practice Gap In HTN Management". Hypertension (HTN) is the most important stroke and cardiovascular disease (CVD) risk factor. Unfortunately, there is substantial under-treatment of HTN. Of the 86 million adults with prevalent HTN in the U.S., 40 million (46%) have inadequately controlled blood pressure (BP). This problem is worse ...

What is the current status of trial NCT03612271?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 395 participants. The study started on 2019-03-01. Estimated completion is 2026-04-30.

What conditions does trial NCT03612271 study?

This clinical trial studies the following conditions: Hypertension.

What interventions are being tested in trial NCT03612271?

The interventions under investigation include: mGlide (BEHAVIORAL).

Who is sponsoring clinical trial NCT03612271?

This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03612271 being conducted?

This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Hypertension

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.